A MASS COMPATIBLE UPLC METHOD FOR THE QUANTIFICATION OF IMPURITIES IN FLUTICASONE PROPIONATE NASAL SPRAY
Objective: The objectives of the present study were to develop and validate a mass compatible ultra-performance liquid chromatography (UPLC) method to quantify the impurities in fluticasone nasal spray, and to establish a suitable container-closure system for the formulation.
Methods: A gradient method was optimized with a flow rate of 0.5 ml/min, detector wavelength-240 nm, run time-25 min and 0.1% Trifluoroacetic acid (TFA) in water as solvent A and Methanol as solvent B.
Results: The developed method was linear over the range of 0.07-1.10 µg/ml for impurity-I, 0.16-2.47 µg/ml for impurity-II, 0.67-10.0 µg/ml for impurity-III, and 1.29-19.3 µg/ml for impurity-IV. The limit of quantification (LOQ) and limit of detection (LOD) were established as 0.07 and 0.02 µg/ml, 0.14 and 0.05 µg/ml, 0.59 and 0.19 µg/ml, 1.06 and 0.35 µg/ml for impurities I-IV respectively. The percent relative standard deviation (%RSD) of the replicate analysis for impurities I-IV, was within the acceptance criteria (0.4, 0.2, 0.3, and 0.1% respectively) that proved the precision of the method. The accuracy of the method was studied from 50%-150% of test concentration and the results ranged from 100.3% to 109.4%. The container-closure compatibility study revealed that the solution stored in the glass container system did not generate any additional peaks in the chromatogram.
Conclusion: Hence, the developed method can be employed by quality testing laboratories to quantify impurities in fluticasone propionate nasal spray. The study also suggests that glass containers could serve as a compatible system for the storage of fluticasone propionate nasal solution.
2. Fuller R, Johnson M, Bye A. Fluticasone propionate-an update on preclinical and clinical experience. Respir Med 1995;89:3-18.
3. Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley Yates PT, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000;356:556-61.
4. Byrro RMD, Cesar IC, Cardoso FFDSS, Mundim IM, Teixeira LDS, Bonfim RR, et al. A rapid and sensitive HPLC-APCI-MS-MS method determination of fluticasone in human plasma: application for a bio equivalency study in nasal spray formulations. J Pharm Biomed Anal 2012;61:38-43.
5. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 2003;117:843-5.
6. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84:25-9.
7. Morris HG. Mechanisms of glucocorticoids action in pulmonary disease. Chest 1985;88:133-41.
8. Pauwels R. Mode of action of corticosteroids in asthma and rhinitis. Clin Allergy 1986;16:281-8.
9. Buscher BAP, Jagfeldt H, Sandman H, Brust-van Schaik R, Van Schaik F, Brull LP. The determination of budesonide and fluticasone in human sputum samples collected from COPD patients using LC-MS/MS. J Chromatogr B 2012;880:6-11.
10. Paczkowska E, Smukowska D, Tratkiewicz E, Bialasiewicz P. HPLC method for simultaneous determination of salmeterol xinafoate and fluticasone propionate for the quality control of dry powder inhalation products. Acta Chromatogr 2015;27:309-20.
11. Akmese B, Sanli S, Sanli N, Asan A. A validated RP-LC method for salmeterol and fluticasone in their binary mixtures and their stress degradation behavior under ICH-recommended stress conditions. J Anal Chem 2014;69:563-73.
12. Angela LB, Mitch SK, James ML. Analysis of ecologically relevant pharmaceuticals in wastewater and surface water using selective solid-phase extraction and UPLC-MS/MS. Anal Chem 2008;80:5021-30.
13. Bardsley B, Smith MS, Gibbon BH. Structure elucidation and spectroscopic analysis of photodegradants of the anti-rhinitis drug fluticasone propionate. Org Biomol Chem 2010;8:1876-80.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 2005. Available from: https://database.ich.org/sites/default/files/Q2%28R1%29%20Guideline.pdf [Last accessed on 10 May 2020]
15. Kunithala VK, Chinthakindi KK, Vemula SK, Garepally PR, Bontha VK. A new rapid and simple analytical method development and validation of estimation of the mycophenolate in dosage form by UPLC technique. Asian J Pharm Clin Res 2012;5:233-7.
16. Maggadani BP, Yasmina J, Harmita H. Development of a direct method of analyzing tranexamic acid levels in whitening cream using reversed phase high-performance liquid chromatography. Int J Appl Pharm 2020;12:88-92.
17. Aher SS, Saudagar RB, Kothari H. Development and validation of RP-HPLC method for simultaneous estimation azilsartan medoxomil and chlorthalidone in bulk and tablet dosage form. Int J Curr Pharm Res 2018;10:21-4.
18. Sharma T, Mishra N, Moitra SS, Sankar DG. A validated RP-HPLC method for estimation of tenofovir disoproxil fumarate in bulk and pharmaceutical formulation. Asian J Pharm Clin Res 2012;5:108-10.
This work is licensed under a Creative Commons Attribution 4.0 International License.